95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Med.
Sec. Pathology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1510225
Aggressive Recurrent Intestinal-Type Adenocarcinoma of the Nasal Cavity: a case report and literature review
Provisionally accepted
Fei Le 1*
Yaoyao Chen 1
Jiawei XU 1
Chengdong Yu 1
Haoyu Shi 1
Ling Luo 1 Dingbang Peng 1 Xiaofang Zhang 2* Wen Chen 2*- 1 Nanchang University, Nanchang, China
- 2 Jiangxi Cancer Hospital, Nanchang, Jiangxi Province, China
Intestinal-type adenocarcinoma (ITAC) of the nasal cavity is a rare, aggressive tumor that presents unique therapeutic challenges, particularly in cases of recurrent disease with intracranial extension. We present the case of a 54-year-old male with recurrent ITAC who demonstrated a remarkable response to a novel triple-therapy approach.This patient lacked the typical risk factors, such as occupational exposure to wood or leather dust, making this case particularly unusual. After failing conventional treatments and experiencing multiple recurrences with progressive intracranial invasion, the patient received an innovative combination of immunotherapy (Toripalimab), targeted therapy (Anlotinib), and chemotherapy (S-1). This unprecedented therapeutic combination resulted in significant tumor volume reduction (from 53.9×42.7 mm to 38.9×18.8 mm) and marked improvement in neurological symptoms, particularly diplopia. To our knowledge, this represents the first case report of successful implementation of this specific triple therapy regimen for recurrent ITAC with intracranial extension.
Keywords: Intestinal-type adenocarcinoma, Nasal Cavity, Immunotherapy, targeted therapy, Recurrence, case report
Received: 12 Oct 2024; Accepted: 28 Mar 2025.
Copyright: © 2025 Le, Chen, XU, Yu, Shi, Luo, Peng, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fei Le, Nanchang University, Nanchang, China
Xiaofang Zhang, Jiangxi Cancer Hospital, Nanchang, Jiangxi Province, China
Wen Chen, Jiangxi Cancer Hospital, Nanchang, Jiangxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.